Comprehensive serologic profile and specificity of maternal and neonatal cord blood SARS-CoV-2 antibodies.
COVID-19
immunity
passive immunity
pregnancy
serology
Journal
AJOG global reports
ISSN: 2666-5778
Titre abrégé: AJOG Glob Rep
Pays: United States
ID NLM: 101777907
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
pubmed:
29
12
2021
medline:
29
12
2021
entrez:
28
12
2021
Statut:
ppublish
Résumé
Initial studies on COVID-19 in pregnancy have demonstrated a range of neutralizing activity, but little has been published on the full profile of SARS CoV-2 related antibodies in maternal and cordblood. This study aimed to describe the profile and specificity of maternal and neonatal cord blood antibody profiles in response to SARS-CoV-2 virus exposure. This was a prospective cohort study of delivering patients at Thomas Jefferson University Hospital from April 2020 to February 2021. The primary objective was to describe unique maternal and fetal antibody epitope titers and specificity in patients with COVID-19 history. Serologic profile was assessed with a multiplex platform. Antigens used were hemagglutinin trimer influenza A (Hong Kong H3); spike trimers for SARS-CoV-2, SARS-CoV-1, Middle East respiratory syndrome coronavirus, and betacoronaviruses HKU-1 and OC43; and spike N-terminal domain, spike receptor-binding domain, and nucleocapsid protein (full length) for SARS-CoV-2. Here, 112 maternal samples and 101 maternal and cord blood pairs were analyzed. Of note, 37 patients had a known history of COVID-19 (positive polymerase chain reaction test) during pregnancy. Of 36 patients, 16 (44%) were diagnosed with COVID-19 within 7 days of delivery. Moreover, 15 of the remaining 76 patients (20%) without a known diagnosis had positive maternal serology. For those with a history of COVID-19, we identified robust immunoglobulin G response in maternal blood to CoV-2 nucleocapsid, spike (full length), and spike (receptor-binding domain) antigens with more modest responses to the spike (N-terminal domain) antigen. In contrast, the maternal blood immunoglobulin M response seemed more specific to spike (full length) epitopes than nucleocapsid, spike (receptor-binding domain), or spike (N-terminal domain) epitopes. There were significantly higher maternal and cord blood immunoglobulin G responses not only to CoV-2 spike (127.1-fold; standard deviation, 2.0; Placental transfer was efficient, with robust nucleocapsid and spike responses. Both nucleocapsid and spike antibody responses should be studied for a better understanding of COVID-19 immunity. Immunoglobulin G antibodies were cross-reactive with related CoV-1 and Middle East respiratory syndrome spike epitopes, whereas immunoglobulin M antibodies, which cannot cross the placenta to provide neonatal passive immunity, were more SARS-CoV-2 specific. Neonatal cord blood may have significantly different fine specificity than maternal blood, despite the high efficiency of immunoglobulin G transfer.
Sections du résumé
BACKGROUND
BACKGROUND
Initial studies on COVID-19 in pregnancy have demonstrated a range of neutralizing activity, but little has been published on the full profile of SARS CoV-2 related antibodies in maternal and cordblood.
OBJECTIVE
OBJECTIVE
This study aimed to describe the profile and specificity of maternal and neonatal cord blood antibody profiles in response to SARS-CoV-2 virus exposure.
STUDY DESIGN
METHODS
This was a prospective cohort study of delivering patients at Thomas Jefferson University Hospital from April 2020 to February 2021. The primary objective was to describe unique maternal and fetal antibody epitope titers and specificity in patients with COVID-19 history. Serologic profile was assessed with a multiplex platform. Antigens used were hemagglutinin trimer influenza A (Hong Kong H3); spike trimers for SARS-CoV-2, SARS-CoV-1, Middle East respiratory syndrome coronavirus, and betacoronaviruses HKU-1 and OC43; and spike N-terminal domain, spike receptor-binding domain, and nucleocapsid protein (full length) for SARS-CoV-2.
RESULTS
RESULTS
Here, 112 maternal samples and 101 maternal and cord blood pairs were analyzed. Of note, 37 patients had a known history of COVID-19 (positive polymerase chain reaction test) during pregnancy. Of 36 patients, 16 (44%) were diagnosed with COVID-19 within 7 days of delivery. Moreover, 15 of the remaining 76 patients (20%) without a known diagnosis had positive maternal serology. For those with a history of COVID-19, we identified robust immunoglobulin G response in maternal blood to CoV-2 nucleocapsid, spike (full length), and spike (receptor-binding domain) antigens with more modest responses to the spike (N-terminal domain) antigen. In contrast, the maternal blood immunoglobulin M response seemed more specific to spike (full length) epitopes than nucleocapsid, spike (receptor-binding domain), or spike (N-terminal domain) epitopes. There were significantly higher maternal and cord blood immunoglobulin G responses not only to CoV-2 spike (127.1-fold; standard deviation, 2.0;
CONCLUSION
CONCLUSIONS
Placental transfer was efficient, with robust nucleocapsid and spike responses. Both nucleocapsid and spike antibody responses should be studied for a better understanding of COVID-19 immunity. Immunoglobulin G antibodies were cross-reactive with related CoV-1 and Middle East respiratory syndrome spike epitopes, whereas immunoglobulin M antibodies, which cannot cross the placenta to provide neonatal passive immunity, were more SARS-CoV-2 specific. Neonatal cord blood may have significantly different fine specificity than maternal blood, despite the high efficiency of immunoglobulin G transfer.
Identifiants
pubmed: 34961853
doi: 10.1016/j.xagr.2021.100046
pii: S2666-5778(21)00044-7
pmc: PMC8697419
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100046Subventions
Organisme : NICHD NIH HHS
ID : R21 HD101127
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104941
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2021 The Authors.
Références
Am J Obstet Gynecol. 2020 Jul;223(1):111.e1-111.e14
pubmed: 32335053
Influenza Other Respir Viruses. 2019 Sep;13(5):438-452
pubmed: 31165580
Nat Immunol. 2021 Jan;22(1):25-31
pubmed: 33154590
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Am J Obstet Gynecol. 2021 Jun;224(6):623-624
pubmed: 33675794
MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1635-1640
pubmed: 33151917
Emerg Microbes Infect. 2020 Dec;9(1):940-948
pubmed: 32357808
Am J Clin Pathol. 2020 Jun 8;154(1):23-32
pubmed: 32441303
Sci Immunol. 2017 Sep 1;2(15):
pubmed: 28864494
J Clin Immunol. 2012 Apr;32(2):300-11
pubmed: 22198680
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1641-1647
pubmed: 33151921
JAMA Netw Open. 2020 Dec 1;3(12):e2030455
pubmed: 33351086
Sci Immunol. 2020 Jul 29;5(49):
pubmed: 32727884
Am J Obstet Gynecol. 2021 Jul;225(1):73.e1-73.e7
pubmed: 33497654
Pathobiology. 2021;88(1):69-77
pubmed: 32950981
Front Immunol. 2019 Oct 23;10:2469
pubmed: 31708922
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Cell Rep. 2021 Mar 2;34(9):108790
pubmed: 33596407
Am J Obstet Gynecol. 2020 Jul;223(1):109.e1-109.e16
pubmed: 32360108
BMJ. 2020 Sep 1;370:m3320
pubmed: 32873575
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
JAMA Pediatr. 2021 Jun 1;175(6):594-600
pubmed: 33512440
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Lancet Infect Dis. 2017 Jul;17(7):e209-e222
pubmed: 28433704
Biochem Biophys Res Commun. 2020 Jun 30;527(3):618-623
pubmed: 32416961
Placenta. 2020 Nov;101:13-29
pubmed: 32911234
Nat Commun. 2021 Mar 22;12(1):1813
pubmed: 33753738
J Infect Dis. 2016 Dec 1;214(11):1666-1671
pubmed: 27655870
PLoS One. 2021 Jun 3;16(6):e0252628
pubmed: 34081747
JAMA Pediatr. 2021 Aug 1;175(8):817-826
pubmed: 33885740
J Infect Dis. 2021 Mar 29;223(6):957-970
pubmed: 33367897